Back to Search
Start Over
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
- Source :
-
European Urology . Nov2023, Vol. 84 Issue 5, pe123-e124. 2p. - Publication Year :
- 2023
- Subjects :
- *RENAL cell carcinoma
*SUNITINIB
*PEMBROLIZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 03022838
- Volume :
- 84
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- European Urology
- Publication Type :
- Academic Journal
- Accession number :
- 172810492
- Full Text :
- https://doi.org/10.1016/j.eururo.2023.08.010